Status: Recruiting
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
This is a prospective phase I dose-escalation study, with the primary objective to access the MTD and find the RP2D of talazoparib, given in combination with standard of care dosing of pacritinib.
Participants needed: 24
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Fox Chase Cancer CenterUpdated: May 3, 2024Locations: 1
Eligibility criteria
Patients must have histologically or cytologically confirmed primary myelofibros... [+8]
Patients may not be receiving any other investigational agents [+6]